FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * SALEKI-GERHARDT AZITA 2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ ABBV ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP, Operations
(Last)         (First)         (Middle)
1 N. WAUKEGAN ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)
5/24/2021
(Street)
NORTH CHICAGO, IL 60064
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.01 par value  5/24/2021    M    12400  A $29.23  128684  D   
Common Stock, $0.01 par value  5/24/2021    M    74520  A $35.88  203204  D   
Common Stock, $0.01 par value  5/24/2021    S    77863  D $116.2431 (1) 125341  D   
Common Stock, $0.01 par value  5/24/2021    S    9057  D $116.7049 (2) 116284  D   
Common Stock, $0.01 par value                 2272 (3) I  Profit sharing trust 
Common Stock, $0.01 par value                 3873 (4) I  By spouse 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option (Right to buy) (5) $29.23  5/24/2021    M        12400   2/17/2013  2/16/2022  Common Stock  12400  $0  0  D   
Option (Right to buy) (5) $35.88  5/24/2021    M        74520   2/14/2014  2/13/2023  Common Stock  74520  $0  0  D   

Explanation of Responses:
(1)  The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.67 to $116.64 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(2)  The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.67 to $116.79 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(3)  Balance in AbbVie Savings program as of May 26, 2021.
(4)  The reporting person disclaims beneficial ownership of all securities held by her spouse.
(5)  Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:
The transactions reported on this Form 4 were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SALEKI-GERHARDT AZITA
1 N. WAUKEGAN ROAD
NORTH CHICAGO, IL 60064


EVP, Operations

Signatures
Steven L. Scrogham, attorney-in-fact for Azita Saleki-Gerhardt 5/26/2021
**Signature of Reporting Person Date
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more AbbVie Charts.